Seminal results, that will drive future development, are expected from the combination of PARPi with decitabine (NCT02878785), particularly in the sub-cohort of TET2 and TET2/DNMT3A-mutant AML for their high sensitivity to DNA damage [135], and from target-restricted studies in IDH1/2 mutant (NCT03953898) and in cohesin mutant (NCT03974217) AML. This evidence concerns the gene IDH1 and acute myeloid leukemia.